Study M587
Study name | Ahmed AT 2020 |
Title | Acylcarnitine metabolomic profiles inform clinically-defined major depressive phenotypes |
Overall design | The aim of this study was to examine whether plasma acylcarnitine profiles can help biochemically distinguish the three phenotypic subtypes of major depressive disorder (MDD): core depression (CD+), anxious depression (ANX+), and neurovegetative symptoms of melancholia (NVSM+). MDD patients (n = 240) were treated with citalopram or escitalopram for eight weeks. Plasma samples collected at baseline and after eight weeks of treatment with citalopram or escitalopram were profiled for short-, medium- and long-chain acylcarnitine levels using AbsoluteIDQ p180-Kit and LC-MS. |
Study Type | Type2; |
Data available | Unavailable |
Organism | Human; |
Categories of depression | Depressive disorder; Depression; Depression; |
Criteria for depression | DSM-IV diagnosed MDD, HAMD-17 > 14 |
Sample size | 92 |
Tissue | Peripheral; Blood; Plasma; |
Platform | MS-based; LC-MS: ultra-performance liquid chromatography with tandem mass spectrometry/MS/MS system with TQ-S triple quadrupole MS/MS (Waters); |
PMID | |
DOI | |
Citation | Ahmed AT, MahmoudianDehkordi S, Bhattacharyya S, et al. Acylcarnitine metabolomic profiles inform clinically-defined major depressive phenotypes. J Affect Disord. 2020;264:90-97. |
Metabolite | Propionylcarnitine; L-Acetylcarnitine; L-Carnitine; Linoelaidylcarnitine; Oleoylcarnitine; L-Octanoylcarnitine; Decanoylcarnitine; Dodecanoylcarnitine; L-Palmitoylcarnitine; Butyryl/Isobutyryl-L-carnitine; Isovaleryl/methylbutyryl-L-carnitine; 3-Methylglutarylcarnitine; Tiglyl/methylcrotyonyl-L-carnitine; Hydroxyisovaleryl/methyl-hydroxybutyryl-L-carnitine; |
